Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients

Inclusion Criteria: 1. ECOG performance score of 0 or 1 2. Adequate liver function (Total serum bilirubin \< twice upper normal limit or Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 3-fold higher than laboratory upper normal limits) 3. Adequate renal function (creatinine clearance \> 50 ml/min) 4. Adequate cardiac function (LVEF\>40%) 5. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. 6. Signed, written informed consent Exclusion Criteria: - 1. Known hypersensitivity or contraindications against Withaferin-A. 2. Presence of an active uncontrolled infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection. 3. Any medical or psychiatric illness which precludes the participant from giving informed consent 4. Pregnancy, lactation, or inadequate contraception.